Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator program to support early-stage startups called Illumina for Startups. ScienceBoard.net recently spoke with Amanda Cashin, PhD, who leads Illumina's accelerator programs in the U.S. and internationally.

The global market for oncology cell and gene therapies reached $1.6 million in 2020 and is expected to reach $2.744 billion in 2021, according to a recent article in Cell and Gene Therapy Business Outlook, a sister subscription-based publication of ScienceBoard.net.

While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021.

NanoString Technologies has released the first high-plex, single-cell in situ dataset from formalin-fixed paraffin-embedded tissue samples generated by its CosMx Spatial Molecular Imager（SMI）.

Automated benchtop synthetic biology systems developer Codex DNA has agreed to acquire Eton Bioscience for $13 million.

While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on the Mesa 2021.

Cellaria has launched a new tumor modeling platform that includes a panel of cell culture media for growing cell types, an extracellular neutral collagen matrix, and protocols for testing new drug compounds.

Synlogic and Ginkgo Bioworks have developed an investigational synthetic biotic medicine for the treatment of homocystinuria（HCU）. The companies will highlight the work at the International Congress of Inborn Errors of Metabolism 2021 to be held November 21-23 in Sydney.

Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator program to support early-stage startups called Illumina for Startups. ScienceBoard.net recently spoke with Amanda Cashin, PhD, who leads Illumina's accelerator programs in the U.S. and internationally.

The global market for oncology cell and gene therapies reached $1.6 million in 2020 and is expected to reach $2.744 billion in 2021, according to a recent article in Cell and Gene Therapy Business Outlook, a sister subscription-based publication of ScienceBoard.net.

Dovetail Genomics has formed what it is calling the Boston Epigenetics Society, a group that will meet four times annually to support epigenetics and epitranscriptomics research and forge relationships between academics and scientists.

Biotechnology company Arbor Biotechnologies recently raised $215 million in a series B financing round to move its lead programs for liver and central nervous system diseases to the clinic.

Mustang Bio has entered into an exclusive licensing agreement with Leiden University Medical Center in Leiden, the Netherlands, for an ex vivo lentiviral gene therapy for the treatment of recombination activating 1 severe combined immunodeficiency.

Jasper Therapeutics and Avrobio have entered a nonexclusive research collaboration to evaluate Jasper's anti-CD117 monoclonal antibody in clinical trials.